ESMO 2022: Summary of ESMO Adjuvant RCC Trials

Axel Bex summarizes the RCC studies that were presented at ESMO 2022, including potential toxicity of ipilimumab/nivolumab, pembrolizumab response rates, and single-agent atezolizumab versus placebo.